Evotec provides cutting-edge testing strategies and best practices for genetic integrity testing of genome-edited pluripotent stem cell lines to support clinical applications.
Public source
Publisher name
Public post
Ensuring the genetic integrity of genome-edited pluripotent stem cell lines is crucial for advancing safe and effective cell therapies. Discover how Evotec tackles these…
Company
Evotec
Pioneering Drug Discovery
- Industry
- Biotechnology Research
- Location
- Hamburg, DE
- Company size
- 1,001–5,000 employees
About Evotec
Evotec is a biotechnology company that is committed to advancing drug discovery and development. Through flexible business models, we collaborate with pharmaceutical companies, biotechs, foundations, and government agencies on a substantial scale. We believe that by working together, we can make a difference in the lives of patients. Our Pipeline Co-Creation model represents our adaptable, multi-modality, fully integrated end-to-end approach to drive collaborations and services across all phases of drug discovery and development – from discovery of novel targets to achieving Proof of Concept in the clinic and into commercial manufacturing. We aspire to contribute data-driven disease understanding and early disease relevance in humans to bring the probability of success up. We select the right modality, which is then propelled forward on our platforms by our passionate people striving for the fastest and most effective ways towards patient impact. This is enabled by convergence of human ingenuity with data and AI. We also offer specific solutions, products, and CRO/CDMO-like services, always in support of the Biopharma R&D innovator. Our more than 4,000 scientists work closely with numerous partners concurrently, delivering fully integrated research and development portfolios or individual projects with the highest quality standards and efficiency, coupled with great science, passion, engagement, and communication.
See moreLatest activity
Latest activity from Evotec
16 signals
Presence & Recognition
Evotec is presenting efforts toward embedding greener chemistry practices in its drug discovery pipeline at the 7th International Conference on Free Chemistry in Lisbon.
Presence & Recognition
Evotec is participating in the Virtual Cell Challenge 2026
Presence & Recognition
Evotec participated in the shaping of predictive biology.
Discover more
Similar signals
Similar public activity from other companies.
Products & Services
REPROCELL
REPROCELL supports cell therapy developers from donor sourcing and clinical iPSC generation through gene editing and GMP manufacturing.
Products & Services
pixlbio
pixlbio offers pixCRISPR, a gene-editing and differentiation service for disease models including LDLR, SERPINA1, ATP7B, OTC, ASS1, ABCB11, PAH, and custom targets.
Products & Services
Ncardia
Ncardia launched the Ncyte IO Safety Panel, a single workflow that combines human iPSC-derived neurons, cardiomyocytes, endothelial cells, melanocytes, hepatocytes, intestinal epithelial cells, and alveolar epithelial cells to compare functional toxicity across multiple tissues.
Products & Services
Syngene International Limited
Syngene International Limited's iPSC platform reprograms PBMCs into T-cells, cardiomyocytes, and neuronal cells for disease-relevant assays.
Products & Services
Stemnovate Limited